

Alfons J M Van Den Eertwegh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8232446/publications.pdf>

Version: 2024-02-01

16
papers

705
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1177
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52. | 1.9 | 3 |
| 2 | Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T cell reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, . | 11.9 | 18 |
| 3 | Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796. | 3.1 | 1 |
| 4 | CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. <i>Frontiers in Immunology</i> , 2021, 12, 697840. | 4.8 | 33 |
| 5 | In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. <i>Oncolmmunology</i> , 2020, 9, 1708066. | 4.6 | 5 |
| 6 | Selective tumor antigen vaccine delivery to human CD169 antigen-presenting cells using ganglioside-liposomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27528-27539. | 7.1 | 54 |
| 7 | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003. | 3.7 | 15 |
| 8 | Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70. | 2.5 | 10 |
| 9 | Autologous tumor cell vaccination combined with systemic CpG-B and IFN- γ promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1025-1035. | 4.2 | 13 |
| 10 | A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327. | 6.4 | 15 |
| 11 | Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolmmunology</i> , 2016, 5, e1105431. | 4.6 | 11 |
| 12 | Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. <i>European Urology</i> , 2016, 70, 416-426. | 1.9 | 51 |
| 13 | New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 271-279. | 1.9 | 34 |
| 14 | Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892. | 7.0 | 127 |
| 15 | Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542. | 7.0 | 114 |
| 16 | Peripheral blood IFN- γ -secreting $V\alpha 24^{+}$ $V\beta 11^{+}$ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. <i>International Journal of Cancer</i> , 2005, 116, 87-93. | 5.1 | 201 |